Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity.
| Autor: | Binu AJ; Department of Cardiology, Christian Medical College, Vellore, India., Kapoor N; Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India.; Non-communicable Disease Unit, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Bhattacharya S; Department of Endocrinology, Indraprastha Apollo Hospital, New Delhi, Delhi, India., Kishor K; Department of Cardiology, Rama Hospital, Karnal, India., Kalra S; Department of Endocrinology, Bharti Hospital, Karnal, India.; University Center for Research & Development, Chandigarh University, Mohali, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heart international [Heart Int] 2023 Dec 01; Vol. 17 (2), pp. 6-11. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023). |
| DOI: | 10.17925/HI.2023.17.2.6 |
| Abstrakt: | Sarcopenic obesity (SO) is a chronic condition and an emerging health challenge, in view of the growing elderly population and the obesity epidemic. Due to a lack of awareness among treating doctors and the non-specific nauture of the associated symptoms, SO remains grossly underdiagnosed. There is no consensus yet on a standard definition or diagnostic criteria for SO, which limits the estimation of the global prevalence of this condition. It has been linked to numerous metabolic derangements, cardiovascular disease (CVD) and mortality. The treatment of SO is multimodal and requires expertise across multiple specialties. While dietary modifications and exercise regimens have shown a potential therapeutic benefit, there is currently no proven pharmacological management for SO. However, numerous drugs and the role of bariatric surgery are still under trial, and have great scope for further research. This article covers the available literature regarding the definition, diagnostic criteria, and prevalence of SO, with available evidence linking it to CVD, metabolic disease and mortality, and an overview of current directives on management. Competing Interests: Disclosures: Aditya John Binu, Nitin Kapoor, Saptarshi Bhattacharya, Kamal Kishor and Sanjay Kalra have no financial or non-financial relationships or activities to declare in relation to this article. (© Touch Medical Media 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|